Nattokinase is a serine protease derived from nattō, exhibiting oral bioavailability and fibrinolytic/anticoagulant properties. It degrades fibrin, fibrinolytic substrates, and PAI-1 to dissolve thrombi while inhibiting platelet aggregation, making it suitable for cardiovascular disease and Alzheimer's disease research.
ZK824859 is an oral available and selective inhibitor of urokinase plasminogen activator (uPA)(IC50s of 79 nM, 1580 nM and 1330 nM for human uPA, tPA, and plasmin, respectively).
PPACK is a synthetic peptide derivative. It also irreversibly and specifically inhibits thrombin-mediated platelet activation by binding with high affinity to the active site of thrombin (Ki = 0.24 nM).